Evidence map›Paper›PMID 9715377›Full record

ReviewEndocrine reviews1998

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

J E Gerich

Registry-linked trialOpen access · bronzeAbstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Endocrine reviews, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01795248 (The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus), which is not on this map. Cited by 83 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
27.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01795248 phase4completedstarted 2012, after this paper: background citation

The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus

Ran2012Enrolled105Registered outcomes18Posted comparisons0ConditionsGestational Diabetes MellitusArmsliraglutide, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 420 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Observational
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. ∆nFGF1 ProtectsOxidative medicine and cellular longevity · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy.Frontiers in cardiovascular medicine · 2017
    Review
  19. Article
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

J E GerichUniversity of Rochester, School of Medicine and Dentistry, Department of Medicine, New York 14642, USA.
University of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the fact that it is the prevalent view that insulin resistance is the main genetic factor predisposing to development of type 2 diabetes, review of several lines of evidence in the literature indicates a lack of overwhelming support for this concept. In fact, the literature better supports the case of impaired insulin secretion being the initial and main genetic factor predisposing to type 2 diabetes, especially 1) the studies in people at high risk to subsequently develop type 2 diabetes (discordant monozygotic twins and women with previous gestational diabetes), 2) the studies demonstrating compete alleviation of insulin resistance with weight loss, and 3) the studies finding that people with type 2 diabetes or IGT can have impaired insulin secretion and no insulin resistance compared with well matched NGT subjects. The fact that insulin resistance may be largely an acquired problem in no way lessens its importance in the pathogenesis of type 2 diabetes. Life style changes (exercise, weight reduction) and pharmacological agents (e.g., biguanides and thiazolidendiones) that reduce insulin resistance or increase insulin sensitivity clearly have major beneficial effects (122, 144-146, 153-155).

Indexed as

Insulin ResistanceDiabetes, GestationalDiabetes Mellitus, Type 2FemaleGlucose Tolerance TestHumansInsulinInsulin SecretionPregnancyProspective StudiesInsulin

Identifiers

PMID9715377
OpenAlexW2076122324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.